Immunic AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Immunic's Vidofludimus Calcium Shows Promise in Multiple Sclerosis Trials
• Immunic's phase 2 CALLIPER trial of Vidofludimus Calcium in progressive multiple sclerosis is expected to report top-line data in April.
• Interim analysis of the phase 3 ENSURE trials for relapsing multiple sclerosis showed positive outcomes, with completion expected in 2026.
• Vidofludimus Calcium targets Nurr1 activation for neuroprotection and DHODH inhibition for anti-inflammatory and antiviral effects in MS.
© Copyright 2025. All Rights Reserved by MedPath